The Current Ratio as of November 2024 (TTM) for Alnylam Pharmaceuticals, Inc. (ALNY) is 2.75

According to Alnylam Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 2.75. This represents a change of -8.46% compared to the average of 3.00 of the last 4 quarters.

Alnylam Pharmaceuticals, Inc. (ALNY) Historical Current Ratio (quarterly & annually)

How has ALNY Current Ratio performed in the past?

The mean historical Current Ratio of Alnylam Pharmaceuticals, Inc. over the last ten years is 5.01. The current 2.75 Current Ratio has changed 5.38% with respect to the historical average. Over the past ten years (40 quarters), ALNY's Current Ratio was at its highest in in the September 2015 quarter at 18.24. The Current Ratio was at its lowest in in the December 2019 quarter at 1.81.

Alnylam Pharmaceuticals, Inc. (ALNY) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Alnylam Pharmaceuticals, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Alnylam Pharmaceuticals, Inc. (ALNY) Average Current Ratio

How has ALNY Current Ratio performed in the past?

The current Current Ratio of Alnylam Pharmaceuticals, Inc. (ALNY) is less than than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

Alnylam Pharmaceuticals, Inc. (ALNY) Current Ratio vs. Peers

How is ALNY’s Current Ratio compared to its peers?

Alnylam Pharmaceuticals, Inc.’s Current Ratio is greater than ProQR Therapeutics N.V. (2.33), greater than Wave Life Sciences Ltd. (1.90), less than Blueprint Medicines Corporation (3.32), less than Apellis Pharmaceuticals, Inc. (4.36), greater than Incyte Corporation (1.87), less than United Therapeutics Corporation (4.58), less than Ultragenyx Pharmaceutical Inc. (2.81), less than BioMarin Pharmaceutical Inc. (4.27), greater than Seagen Inc. (2.67), less than Exelixis, Inc. (3.93), less than Halozyme Therapeutics, Inc. (10.36), less than Krystal Biotech, Inc. (7.97), less than Madrigal Pharmaceuticals, Inc. (5.98), less than Reata Pharmaceuticals, Inc. (6.75), less than IVERIC bio, Inc. (18.63), less than Amylyx Pharmaceuticals, Inc. (4.55), less than Karuna Therapeutics, Inc. (19.31), less than Day One Biopharmaceuticals, Inc. (14.62),

Build a custom stock screener for Alnylam Pharmaceuticals, Inc. (ALNY) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Alnylam Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Alnylam Pharmaceuticals, Inc. (ALNY) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Alnylam Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.